Recombinant Fragment Predicted to work with:
Recombinant fragment: AYVVPWQDPW EPFYVAGGKV PTFDERFRQY GFNRISQACE LHVAGFDFEV LNEGFLVHKG FKEALKFHPQ KEAENQHNKI LYRQFKQELK AKYPNSPRRC, corresponding to C terminal amino acids 316-415 of Human B3GNT with a proprietary tag (NP_006867).
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent dilution.
Use a concentration of 10 µg/ml.
FunctionCan initiate the synthesis or the elongation of the linear poly-N-acetyllactosaminoglycans.
Tissue specificityIn the adult, highly expressed in heart, brain, skeletal muscle and kidney and to a lesser extent in placenta, pancreas, spleen, prostate, testis, ovary, small intestine and colon. Very weak expression in lung, liver, thymus and peripheral blood leukocytes. In fetal highly expressed in brain and kidney and to a lesser extent in lung and liver.
PathwayProtein modification; protein glycosylation.
Detection limit for ab118083 is 3 ng/ml as a capture antibody.
This antibody has only been tested against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.
References for Anti-B3GNT antibody (ab118083)
has not yet been referenced specifically in any publications.
Publishing research using
? Please let us know so that we can cite the reference in this datasheet